<DOC>
	<DOCNO>NCT01336972</DOCNO>
	<brief_summary>The purpose trial determine short-term effect dose regimen tolvaptan study patient autosomal dominant polycystic kidney disease ( ADPKD ) various level renal function .</brief_summary>
	<brief_title>Short-Term Renal Hemodynamic Effects Tolvaptan Subjects With Autosomal Dominant Polycystic Kidney Disease ( ADPKD )</brief_title>
	<detailed_description>This trial characterize effect tolvaptan steady-state subject eGFR ( Estimated Glomerular Filtration Rate ) &gt; 60 , 60-30 &lt; 30 mL/min*1.73 m2 design provide data support continue use new introduction tolvaptan subject renal impairment due ADPKD . Subjects titrate high possible split-dose tolvaptan use study ADPKD patient assessed action drug renal hemodynamics , pharmacokinetic pharmacodynamic parameter subject various level renal function . The reversibility change withdrawal drug determine . Acute transitory effect kidney volume also explore .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney , Autosomal Dominant</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Diagnosis ADPKD Ravine criterion Renal replacement therapy Use therapy purpose affect PKD cyst Evidence significant renal disease , eg active glomerular nephritidies , renal cancer , single kidney Significant riskfactors renal impairment , eg chronic use diuretic , advance diabetes , use nephrotoxic drug History significant coagulation defect hemorrhagic diathesis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>